Boston Scientific Says Dead-End SEC Probe Sinks Stock Suit
By Brian Dowling · January 4, 2022, 4:50 PM EST
The U.S. Securities and Exchange Commission is not bringing securities claims against Boston Scientific for halting the production of its Lotus Edge heart device, the company said Monday as it sought...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login